Physician profile
Eric Goldberg
NPI 1093913642
$2,914.52
in general payments reported to CMS, 2019-2025
25 companies · $681 in 2025
The $681 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $296 · 2021: $133 · 2022: $637 · 2023: $407 · 2024: $480 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,567.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $559.98 | 2022-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $498.52 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Gilead Sciences, INC. | $349.42 | 2020-2025 | |
| Lilly USA, LLC | $243.02 | 2021-2024 | Zepbound |
| Pfizer INC. | $218.44 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $147.22 | 2025 | Fanapt, Hetlioz |
| Astrazeneca Pharmaceuticals Lp | $138.93 | 2023-2025 | Farxiga, Breztri |
| Astellas Pharma US INC | $130.11 | 2024-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.56 | 2020-2024 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $85.25 | 2019-2022 | |
| Baxter Healthcare | $82.56 | 2022 | |
| Abbott Laboratories | $48.68 | 2021-2023 | Freestyle Libre 3 |
| Dexcom, INC. | $47.71 | 2022-2023 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $41.98 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $35.45 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $29.56 | 2024 | Leqembi |
| Vistapharm, INC. | $27.32 | 2021 | |
| Merck Sharp & Dohme LLC | $24.20 | 2020 | |
| Xeris Pharmaceuticals, INC. | $22.44 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $21.28 | 2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $18.48 | 2025 | Eliquis |
| Currax Pharmaceuticals LLC | $14.92 | 2025 | Contrave |
| Exact Sciences Corporation | $14.31 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $13.61 | 2019 | |
| Horizon Therapeutics Plc | $12.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Goldberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.